Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in
Metastatic Renal Cell Carcinoma: Lessons for the Era of
Immunotherapy

J 2024

Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy

BÜCHLER, Tomáš and Alexandr POPRACH

Basic information

Original name

Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy

Authors

BÜCHLER, Tomáš (203 Czech Republic) and Alexandr POPRACH (203 Czech Republic, belonging to the institution)

Edition

Targeted Oncology, Dordrecht, Springer, 2024, 1776-2596

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 5.400 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s11523-023-01031-y

UT WoS

001155895200001

Keywords in English

Metastatic Renal Cell Carcinoma; Tyrosine Kinase Inhibitor Therapy

Abstract

V originále

Several regimens combining immunotherapy and tyrosine kinase inhibitors (TKIs) have recently been validated for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). While immunotherapy is typically discontinued after 2 years in patients who neither progress nor experience limiting toxicity, according to the protocols of most recent phase III clinical trials, TKIs are to be continued until disease progression or the emergence of limiting toxicity. However, the prolonged use of TKIs is associated with significant toxicity and financial costs. This has sparked considerable debate about whether TKIs can be safely discontinued, particularly in mRCC patients who have achieved a verified complete response. This concise review examines the available evidence on TKI discontinuation in the context of mRCC management.

Links

NU21-03-00539, research and development project

Name: Vliv stresu endoplazmatického retikula na imunitní stav nádorů a účinnost imunoterapie při léčbě ovariálního a renálního karcinomu

Investor: Ministry of Health of the CR, The effect of endoplasmic reticulum stress on the immune status of tumors and the efficiency of immunotherapy in the treatment of ovarian and renal cell carcinoma, Subprogram 1 - standard

Citovat

BÜCHLER, Tomáš and Alexandr POPRACH. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy. Targeted Oncology. Dordrecht: Springer, 2024, vol. 19, No 2, p. 175-180. ISSN 1776-2596. Available from: https://dx.doi.org/10.1007/s11523-023-01031-y.

@article{2423259,
   author = {Büchler, Tomáš and Poprach, Alexandr},
   article_location = {Dordrecht},
   article_number = {2},
   doi = {http://dx.doi.org/10.1007/s11523-023-01031-y},
   keywords = {Metastatic Renal Cell Carcinoma; Tyrosine Kinase Inhibitor Therapy},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy},
   url = {https://link.springer.com/article/10.1007/s11523-023-01031-y},
   volume = {19},
   year = {2024}
}

TY  - JOUR
ID  - 2423259
AU  - Büchler, Tomáš - Poprach, Alexandr
PY  - 2024
TI  - Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy
JF  - Targeted Oncology
VL  - 19
IS  - 2
SP  - 175-180
EP  - 175-180
PB  - Springer
SN  - 17762596
KW  - Metastatic Renal Cell Carcinoma
KW  - Tyrosine Kinase Inhibitor Therapy
UR  - https://link.springer.com/article/10.1007/s11523-023-01031-y
N2  - Several regimens combining immunotherapy and tyrosine kinase inhibitors (TKIs) have recently been validated for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). While immunotherapy is typically discontinued after 2 years in patients who neither progress nor experience limiting toxicity, according to the protocols of most recent phase III clinical trials, TKIs are to be continued until disease progression or the emergence of limiting toxicity. However, the prolonged use of TKIs is associated with significant toxicity and financial costs. This has sparked considerable debate about whether TKIs can be safely discontinued, particularly in mRCC patients who have achieved a verified complete response. This concise review examines the available evidence on TKI discontinuation in the context of mRCC management.
ER  -

BÜCHLER, Tomáš and Alexandr POPRACH. Planned Discontinuation of Tyrosine Kinase Inhibitor Therapy in Metastatic Renal Cell Carcinoma: Lessons for the Era of Immunotherapy. \textit{Targeted Oncology}. Dordrecht: Springer, 2024, vol.~19, No~2, p.~175-180. ISSN~1776-2596. Available from: https://dx.doi.org/10.1007/s11523-023-01031-y.

Detailed Information on Publication Record